Shenzhen-listed Hubei Biocause Pharmaceutical Co (Biocause) has announced that it plans to purchase 60% of Huarui Insurance Sales Co held by its subsidiary Guohua Life Insurance.
Please login to read the full news
Note that your comment may be edited or removed in the future, and that your comment may appear alongside the original article on websites other than this one.
more »
Brought to you by